Allegro has two pipeline projects: Risuteganib, an integrin-regulating therapy being evaluated in dry atrophic macular degeneration, and ALG-1007, a topical integrin regulator being evaluated in dry eye syndrome, the report said. These assets are expected to expand Bausch’s pipeline and open up the possibility to dip into the commercial market for the indications, especially in dry AMD.
Drug sales in the dry AMD and DES markets are expected to grow, the report said.
Read more details and the full analysis here.
More articles on surgery centers:
Florida eye practice to expand
U of Michigan doctor’s work on ‘Mini-Vit’ to help precision medicine in ophthalmology
7 ophthalmology deals in the last 90 days
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.